
|Articles|March 7, 2022
Daily Medication Pearl: Aggrenox (Aspirin/ER, Dipyridamole)
Author(s)Saro Arakelians, PharmD
Aggrenox is indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis.
Advertisement
Medication Pearl of the Day: Aggrenox (Aspirin/ER, Dipyridamole)
Indication: Aggrenox is a combination antiplatelet agent indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis.
Insight:
- Dosing: One capsule twice daily (morning and evening) with or without food.
- Dosage forms: Capsule 25 mg aspirin/200 mg extended-release dipyridamole.
- Adverse events (AEs): The most frequently reported AEs (>10% and greater than placebo) were headache, dyspepsia, abdominal pain, nausea, and diarrhea.
- Mechanism of action: The antithrombotic action of Aggrenox is the result of the additive antiplatelet effects of dipyridamole and aspirin.
- Manufacturer: Boehringer Ingelheim
Sources:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
2
Enlicitide Meaningfully Lowers LDL-C at 24 Weeks in Patients At Risk for ASCVD Events
3
SGLT2 Inhibitors in T2D Lower 5-Year Risk of CKD and Acute Kidney Injury
4
Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment
5


























